Preclinical development

Structure of the eye
#Mogrify #Preclinical development #Retinal diseases #Transcriptomics

MOGRIFY-derived transcription factors preserve functional vision

Mogrify will present preclinical proof-of-concept data at FLORetina-ICOOR 2026 in support its first-in-class therapy designed to protect and regenerate the retina in patients with retinal disorders.  The company’s lead programme uses transcription factor-mediated direct reprogramming to convert müller glial cells into functional photoreceptors within the retina.  … Read More

#News

Vaccine research
#Contract Research Organisations (CROs) #Drug discovery #Preclinical development #Whitepaper

Whitepaper: How important is onshoring preclinical research?

This Whitepaper by Crown Bioscience outlines the onshoring strategies for pharmaceutical companies and how this affects decisions to work with contract research organisations (CRO) at home or abroad. Readers will learn: The regulatory developments driving onshoring strategies Industry considerations for choosing a CRO When onshoring needs to be considered Download… Read More

#Editor's Choice #News

#Human cell models #Mergers and acquisitions #Preclinical development #Revvity

Revvity acquires human cell model specialist

Revvity has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specialising in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases.   The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s… Read More

#Business & Investment #News

Human liver
#Cell Science #Drug discovery #New approach methodologies (NAMs) #Organoids #Preclinical development

Download the Factsheet: MASLD research needs better liver models

A new resource is now available to download for free. MASLD drug development is limited by models that don’t reflect human liver biology. HUB’s patient-derived liver organoids retain donor genetics, architecture and physiology. Download the Factsheet to learn: How organoids recapitulate steatosis and fibrosis Which readouts support target validation… Read More

#News

Cell and gene therapy
#Drug discovery #Gene therapy #Metabolic diseases #Preclinical development

Study proves preclinical efficacy of gene therapy for metabolic disorder 

Genespire, in collaboration with researchers at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), has revealed preclinical data supporting the potential of its liver-directed immune-shielded lentiviral gene therapy approach to treat metabolic disorder methylmalonic acidemia (MMA).  The findings, published in the Journal of Hepatology, show that a single systemic administration of a lentiviral vector… Read More

#News

Breast cancer research
#Breast cancer #Clinical development #Drug discovery #Partnership #Preclinical development

Astex partners with Genentech on breast cancer treatments 

Pharmaceutical company Astex has entered an exclusive worldwide research agreement with Genentech to identify treatments for breast cancer.  The partnership will aim to find small molecule drug candidates with selective inhibitory activity as potential treatments for breast cancer, leveraging Astex’s fragment-based drug discovery programme.  Under the terms of… Read More

#News

Medical research
#Evotec #Inflammatory diseases #Preclinical development

Evotec nominates PDC for inflammatory skin disease programme 

Evotec has nominated its small molecule preclinical development candidate (PDC) as it advances a programme for inflammatory skin diseases.  The programme, developed as part of an alliance in medical dermatology with Almirall announced in 2022, will develop novel treatments for immune-mediated inflammatory skin diseases with high unmet… Read More

#News

Monoclonal antibody
#Antibody #iBio #Obesity #Preclinical development #Weight loss

Twice-yearly antibody shows strong therapeutic potential for weight-loss

iBio has announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate supported by preclinical data.  The findings will be presented during an oral session at ObesityWeek 2025, taking place 4-7 November in Atlanta, USA. … Read More

#News #Trending News

#Autoimmune disease #Monte Rosa Therapeutics #Preclinical development

Monte Rosa announces results for autoimmune disease treatment 

Biotechnology company Monte Rosa Therapeutics has released preclinical data on MRT-6160, a molecular glue degrader (MGD) to treat autoimmune and inflammatory diseases.  The findings reveal MRT-6160, a first-in-class VAV1-directed MGD, inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly in a spontaneous autoimmune… Read More

#News

Colon cancer
#Colorectal cancer #Larkspur Biosciences #Oncology #Preclinical development #Solid tumours

First degrader of lipid kinase PIP4K2C shows promise in colon cancer

Larkspur Biosciences has announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumours.   The announcement was made at ACS Fall 2025, a meeting of the American Chemical Society in Washington,… Read More

#Cancer Research #News

#AI / data analytics / healthtech / informatics #Drug discovery #Non-animal model (NAM) #Organ-on-a-chip #Preclinical development

What comes after animal models?  

Mariana Argenziano, Associate Director Manufacturing Technologies, and Jeroen de Groot, Divisional Chief Executive Officer at Ncardia, explore how human-relevant preclinical research can move the industry past its reliance on animal models.   In April 2025, the US Food and Drug Administration (FDA) released a roadmap to reducing animal… Read More

#Exclusive Content

Brain inflammation
#Neuroinflammation #Neuroscience #Preclinical development #ReAlta

Pegtarazimod reduces brain inflammation, says new study data

A new study has shown that pegtarazimod reduces microglial activation associated with pathogenic neuroinflammation in hypoxic ischaemic encephalopathy (HIE), as well as neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.  The article in the American Journal of Perinatology highlights that pegtarazimod reduces… Read More

#News

Neuroscience
#Assays #Guide #iPSC #Neuroscience #Preclinical development

Guide: 10 practical tips for reliable MEA experiments in preclinical neuroscience

Combining human iPSC-derived neurons with multi-electrode array (MEA) assays can provide powerful insights into synaptic connectivity, network dynamics, and functional maturation. However, MEA experiments can be challenging, with small changes in cell culture conditions dramatically impacting results. In this expert Guide, bit.bio’s Field Applications Scientist shares key considerations for improving… Read More

#News